glp-1 eye Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?) GLP-1s Linked to Sudden, Rare

(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM

She defended the use of injections for weight loss, saying, "Someone like me could have a bottomless appetite for sweets, so I think those drugs can be good." The star also spoke to People, opening up about her unhealthy relationship with food and exercise

GLP-1 medicines can be a valuable option for some womenbut they work best as part of a compassionate, medically supervised plan that respects both metabolic health and menopausal wellbeing

The major source of GLP-1 in the body is the intestinal L cell that secretes GLP-1 as a gut hormone